Soligenix, Inc. Common Stock
$0.37
Market Cap
$8.16M
Shares Outstanding
21.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 5, 1994
Round Lot
100
Locale
US
Day Open
$0.37
Day High
$0.39
Day Low
$0.37
Volume
257.4K
VWAP
$0.38
Prev Close
$0.38
Transactions
--
Acc. Volume
--
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Soligenix, Inc. Common Stock (SNGX) closed the 2026-09-18 session at $0.37, down 1.36% versus the previous close (-0.01). The stock opened at $0.37 and traded between $0.37 and $0.39 during that session. Session trading volume was 257K shares. The volume-weighted average price (VWAP) is $0.38.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Soligenix, Inc. Common Stock has a market capitalization of $8.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SNGX is listed on the XNAS exchange. The company employs approximately 14 people. Soligenix, Inc. Common Stock is headquartered in PRINCETON, NJ. The recorded listing date is 1994-04-05.
On this page you can find market SNGX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.